Showing results (31-40 of 47) with videos related to
Sort By:
Pageof 5
Bioorganic & Medicinal Chemistry Letters|October 1, 2011
Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitisJill M Scott, Christopher Baccei, Gretchen Bain, et al.Molecular Pharmacology|September 16, 2015
Structural Basis for Inhibition of Human Autotaxin by Four Potent Compounds with Distinct Modes of BindingAdam J Stein, Gretchen Bain, Pat Prodanovich, et al.British Journal of Clinical Pharmacology|July 19, 2012
Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitorGretchen Bain, Christopher D King, Kevin Schaab, et al.The Journal of Pharmacology and Experimental Therapeutics|October 19, 2016
Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver FibrosisGretchen Bain, Kristen E Shannon, Fei Huang, et al.The Journal of Pharmacology and Experimental Therapeutics|April 14, 2011
Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammationGretchen Bain, Daniel S Lorrain, Karin J Stebbins, et al.Bioorganic & Medicinal Chemistry Letters|November 17, 2009
5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitorNicholas Stock, Christopher Baccei, Gretchen Bain, et al.Journal of Medicinal Chemistry|September 11, 2009
5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103)John H Hutchinson, Yiwei Li, Jeannie M Arruda, et al.The Journal of Pharmacology and Experimental Therapeutics|September 15, 2009
Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammationDaniel S Lorrain, Gretchen Bain, Lucia D Correa, et al.Proceedings of the National Academy of Sciences of the United States of America|December 17, 2008
The nuclear membrane organization of leukotriene synthesisAsim K Mandal, Phillip B Jones, Angela M Bair, et al.Nature Medicine|August 24, 2004
The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysmLei Zhao, Michael P W Moos, Rolf Gräbner, et al.Pageof 5